Trial Profile
Prospective, Single-Arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment-Naïve Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2024
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 01 Sep 2023 Planned End Date changed from 18 Feb 2026 to 31 Mar 2026.
- 01 Sep 2023 Planned primary completion date changed from 18 Feb 2026 to 31 Mar 2026.
- 03 Aug 2023 Planned End Date changed from 31 Mar 2026 to 18 Feb 2026.